Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 1, 2013, Pages 215-223

  Jakab, Annamaria ^a   Winter, Serge ^a   Raccuglia, Marc ^a   Picard, Frank ^a   Dumitras, Swati ^a   Woessner, Ralph ^a   Mistry, Sanket ^b   Chudasama, Jayraj ^b   Guttikar, Swati ^b   Kretz, Olivier ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Veeda Clinical Research India   (India)

Author keywords

AFQ056; Human plasma; LC MS MS; Mavoglurant; mGluR5; Recovery; Validation

Indexed keywords

AFQ056; HUMAN PLASMAS; LC-MS/MS; MAVOGLURANT; MGLUR5; VALIDATION;

ACETIC ACID; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; LITHIUM; MASS SPECTROMETRY; METHANOL; POLYSACCHARIDES; RECOVERY; SODIUM;

PLASMA (HUMAN);

ANTICOAGULANT AGENT; HEPARIN; INDOLE DERIVATIVE; ION; MAVOGLURANT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5;

ARTICLE; BLOOD; CALIBRATION; CHEMICAL MODEL; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PLASMA; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME;

ANTICOAGULANTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HEPARIN; HUMANS; INDOLES; IONS; MODELS, CHEMICAL; PLASMA; RECEPTORS, METABOTROPIC GLUTAMATE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84872362340     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6456-y     Document Type: Article

References (12)

1. Cole P (2012) Mavoglurant. Drugs Future 37:7-12
2. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 130(4S, Suppl):1007S-1015S
3. Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322
4. Dölen G, Bear MF (2008) Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586(6):1503-1508
5. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, Gomez-Mancilla B, Nelson DL, Willemsen R, Gasparini F, Oostra BA (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42(3):311-317
6. Gregoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17(4):270-276
7. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Hariry S, Vandemeulebroecke M, Johns D, Gomez-Mancilla B (2010) AFQ056 treatment of severe levodopa- induced dyskinesias: proof of concept study. Mov Disord 25(suppl2):321 [14th Int Congr Parkinson's Dis Mov Disord (June 13-17, Buenos Aires) 2010]
8. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopainduced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26(7):1243-1250
9. Jacquemont S, Curie A, Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3(64):64ra1
10. Walles M, Wolf T, Gschwind HP, Krauser J, Woessner R, Chakraborty A, Ufer M, Swart P (2012) Absorption and disposition of mavoglurant (AFQ056) in healthy volunteers (The 19th International Symposium on Microsomes and Drug Oxidations and 12th European ISSX Meeting (June 17-21, 2012) P195
11. Chakraborty A, Ufer M, Bhad P, Vandemeulebroecke M, Gomez-Mancilla B, Bell D, Winter S (2012) Lack of pharmacokinetic interaction between the novel mGluR5 antagonist AFQ056 and levodopa/carbidopa in healthy volunteers. Mov Disord 27(Suppl 1):456
12. FDA guidance for industry, bioanalytical method validation, US department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2001)